Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.8504
Abstract: This secondary analysis examines the local-regional failure, distant failure, disease-free survival, and overall survival in patients with esophageal cancer who underwent definitive chemoradiotherapy during NRG Oncology randomized clinical trials. read more here.
Keywords: oncology; esophageal cancer; nrg oncology; patients esophageal ... See more keywords
Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34141
Abstract: BACKGROUND To test whether nomograms developed by NRG Oncology for oropharyngeal squamous cell carcinoma (OPSCC) patients could be validated in an independent population-based sample. METHODS The authors tested nomograms for estimating progression-free survival (PFS) and… read more here.
Keywords: cancer; validation; nrg oncology; complete cases ... See more keywords
NRG Oncology NRG-GI007 trial-in-progress: Phase I study of OBP-301 (Telomelysin) and definitive chemoradiation (CRT) for patients with locally advanced esophageal and gastroesophageal adenocarcinoma who are not candidates for surgery.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.tps262
Abstract: TPS262Background: Definitive CRT is a standard-of-care for patients with medically inoperable esophageal cancer (EC, NEJM 326:1593). The NRG/RTOG 0436 study of cisplatin/paclitaxel and RT (+/- cetu... read more here.
Keywords: nrg oncology; nrg gi007; study; crt ... See more keywords
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00164
Abstract: PURPOSE To assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM). The primary objective was OS, and secondary objectives included… read more here.
Keywords: oncology; nrg oncology; oncology rtog1205; pfs ... See more keywords